Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

GW Pharma Climbs on Strong Analyst Forecast

By Pharmaceutical Processing | October 8, 2013

NEW YORK (AP) — Shares of GW Pharmaceuticals jumped Monday after a Canaccord Genuity analyst raised her price target on the stock, citing positive clinical trial data for GW’s drug Sativex.

THE SPARK: Analyst Ritu Baral maintained a “Buy” rating on the shares and raised her price target to $26 from $22. She said peak sales of Sativex in the U.S. and European Union could surpass $2 billion a year.

Sativex is a cannabinoid-based spray. It is approved in Europe as a treatment for spasticity caused by multiple sclerosis, and Baral said she thinks a study of the drug as a treatment for pain caused by cancer will be successful. She expects GW to report data from that study in mid-2014.

THE BIG PICTURE: Sativex is on the market in 11 countries including the U.K., Germany, and Spain, and sales in GW’s latest fiscal quarter totaled $760,000. GW’s partner Almirall is getting ready to launch the drug in other countries. Sativex hasn’t been approved in the U.S.

Sativex is also being studied as a treatment for pain caused by cancer and nerve damage. GW Pharmaceuticals, which is based in Wilshire, U.K., is also running clinical trials of treatments for type 2 diabetes, ulcerative colitis, and schizophrenia.

On Wednesday GW said Sativex did not affect patients’ cognition or mood in a clinical study. Baral said that’s significant because MS patients often stop taking Marinol — a drug that contains synthetic THC — because of those side effects.

SHARE ACTION: U.S. shares of GW Pharmaceuticals surged $9.50, or 38.5 percent, to $34.20 in afternoon trading. The company went public in May with an IPO that priced at $8.90 a share.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE